Vanguard Group Inc Cardiff Oncology, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,728,334 shares of CRDF stock, worth $7.53 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,728,334
Previous 3,115,369
19.68%
Holding current value
$7.53 Million
Previous $9.78 Million
20.06%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CRDF
# of Institutions
126Shares Held
25.8MCall Options Held
1.01MPut Options Held
293K-
Black Rock Inc. New York, NY2.63MShares$5.31 Million0.0% of portfolio
-
Blair William & CO Chicago, IL2.52MShares$5.1 Million0.02% of portfolio
-
Laurion Capital Management LP New York, NY1.8MShares$3.63 Million0.11% of portfolio
-
Geode Capital Management, LLC Boston, MA1.5MShares$3.03 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.42MShares$2.87 Million0.01% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $87.5M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...